AVX-470

Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome

(2013) Maria I. Vazquez-Roque et al.   ADVANCES IN THERAPY

Non-Systemic Drugs: A Critical Review

(2012) Dominique Charmot   CURRENT PHARMACEUTICAL DESIGN

Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages

(2011) Raja Atreya et al.   GASTROENTEROLOGY

Etanercept attenuates TNBS-induced experimental colitis: role of TNF-α expression

(2011) Ana Paula Ribeiro Paiotti et al.   JOURNAL OF MOLECULAR HISTOLOGY

Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease

(2011) J. T. Dudley et al.   Science Translational Medicine

Local injection of infliximab in severe fistulating perianal Crohn’s disease: an open uncontrolled study

(2011) L. Alessandroni et al.   Techniques in Coloproctology

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

(2010) Jun Fang et al.   ADVANCED DRUG DELIVERY REVIEWS

Emerging roles of lymphatics in inflammatory bowel disease

(2010) J. Steven Alexander et al.   Annals of the New York Academy of Sciences

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

(2010) Peter C Taylor   CURRENT OPINION IN PHARMACOLOGY

State-of-the-Art: Immunosuppression and Biologic Therapy

(2010) William J. Sandborn   DIGESTIVE DISEASES

Importance of disrupted intestinal barrier in inflammatory bowel diseases

(2010) Saʼad Y. Salim et al.   INFLAMMATORY BOWEL DISEASES

Neonatal Fc Receptor: From Immunity to Therapeutics

(2010) Timothy T. Kuo et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Essential role for mast cell tryptase in acute experimental colitis

(2010) M. J. Hamilton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

(2009) Zehra Kaymakcalan et al.   CLINICAL IMMUNOLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS